Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.

Advertisement

Related Content

How US Can Learn From Biosimilar Implementation In EU
Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven
European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel